Woodland Pharmaceuticals launches Woodland Translational Research Canada

WORCESTER, Mass. - Sept. 18, 2014 - PRLog -- Boston, MA, September 19, 2014:  WOODLAND PHARMACEUTICALS announces the formation of “Recherche Translationnelle Woodland Canada Inc.” in Laval, Quebec, Canada, formed to contribute its tumor banking expertise to the PreThera Research consortium, an initiative funded by the Canadian Government to enroll cancer patients in long-term tumor tracking projects.   Recherche Translationnelle Woodland Canada Inc., also known as Woodland Translational Research Canada will be hosted at the National Center for Experimental Biology, known by its French acronym CNBE-INRS, a state of the art animal preclinical research facility in Laval, Quebec.  More news about PreThera Research and our new strategic alliance with the CNBE-INRS in Laval just outside Montreal, Quebec, Canada will be forthcoming in the next month.

About Woodland Pharmaceuticals

Woodland Pharmaceuticals is a preclinical contract research organization (CRO) offering in vivo, preclinical, efficacy modeling services in Worcester, MA.  Woodland Pharmaceuticals was founded by Michael Briggs Ph.D. with a focus in oncology and the physiological dysfunctions predisposing to cancers.  It has a stated mission to improve the laboratory modeling of refractory drug resistant human cancers.  The alliances with our Canadian partners PreThera Research and CNBE-INRS will facilitate and strengthen this mission substantially.